Grass Pollen Allergy – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Grass Pollen Allergy – Pipeline Review, H1 2020’, provides an overview of the Grass Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy

– The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects

– The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

Biomay AG

DC4U BV

HAL Allergy BV

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Grass Pollen Allergy – Overview

Grass Pollen Allergy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Grass Pollen Allergy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Grass Pollen Allergy – Companies Involved in Therapeutics Development

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

Biomay AG

DC4U BV

HAL Allergy BV

Regeneron Pharmaceuticals Inc

Grass Pollen Allergy – Drug Profiles

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-32 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized grass pollen [timothy (Phleum pratense)] allergen extract – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Grass Pollen Allergy – Dormant Projects

Grass Pollen Allergy – Discontinued Products

Grass Pollen Allergy – Product Development Milestones

Featured News & Press Releases

Dec 20, 2019: ASIT biotech discloses next steps following gp-ASIT+ phase III results

Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme

Nov 25, 2019: ASIT biotech gp-ASIT+ phase III trial in Grass Pollen Allergy did not meet the primary endpoint

Oct 17, 2019: ASIT biotech mode of action study of gp-ASIT+ for Grass Pollen Allergy published in The Journal of Allergy and Clinical Immunology (JACI)

Sep 26, 2019: ASIT biotech Firmly on Course for Readout of Phase III Clinical Study in Grass Pollen Allergy

Sep 05, 2019: Successful pollen season confirms Asit Biotech on track for phase III results of gp-ASIT+ in December 2019

Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial

May 02, 2019: ASIT biotech announces the achievement of new clinical and corporate development milestones

Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update

Mar 29, 2019: ASIT biotech’s scientific advisory boards (SAB) provide positive recommendations on the clinical development of gp-ASIT+

Mar 05, 2019: ASIT biotech Reveals the Mode of Action of Its Lead Immunotherapy Product for Allergic Rhinitis, gp-ASIT+, in The Journal of Allergy and Clinical Immunology (JACI)

Jan 31, 2019: First patient treated with gp-ASIT+ within the framework of the confirmatory Phase III study in grass pollen rhinitis

Jan 16, 2019: Ongoing Restructuring of ASIT biotech Organization to Maximize the Success of gp-ASIT+ in Grass Pollen Rhinitis

Nov 19, 2018: ASIT biotech launches its confirmatory phase III clinical study with gp-ASIT+ in grass pollen rhinitis prevention following the investigator meeting hosted in Prague (Czech Republic)

Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Grass Pollen Allergy, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Grass Pollen Allergy – Pipeline by ALK-Abello AS, H1 2020

Grass Pollen Allergy – Pipeline by Allergy Therapeutics Plc, H1 2020

Grass Pollen Allergy – Pipeline by ASIT Biotech SA, H1 2020

Grass Pollen Allergy – Pipeline by Biomay AG, H1 2020

Grass Pollen Allergy – Pipeline by DC4U BV, H1 2020

Grass Pollen Allergy – Pipeline by HAL Allergy BV, H1 2020

Grass Pollen Allergy – Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Grass Pollen Allergy – Dormant Projects, H1 2020

Grass Pollen Allergy – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Grass Pollen Allergy, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports